Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK

Pierre Johansen, Barrie Chubb, Barnaby Hunt, Samuel J. P. Malkin, Anna Sandberg, Matthew Capehorn

Open source

DOI
10.1007/s12325-020-01337-7
Published
2020-04-18
Container
Advances in Therapy
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s12325-020-01337-7,
  title = {Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK},
  author = {Pierre Johansen and Barrie Chubb and Barnaby Hunt and Samuel J. P. Malkin and Anna Sandberg and Matthew Capehorn},
  year = {2020},
  journal = {Advances in Therapy},
  doi = {10.1007/s12325-020-01337-7},
  url = {https://doi.org/10.1007/s12325-020-01337-7}
}

RIS

TY  - JOUR
TI  - Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
AU  - Pierre Johansen
AU  - Barrie Chubb
AU  - Barnaby Hunt
AU  - Samuel J. P. Malkin
AU  - Anna Sandberg
AU  - Matthew Capehorn
PY  - 2020
JO  - Advances in Therapy
DO  - 10.1007/s12325-020-01337-7
UR  - https://doi.org/10.1007/s12325-020-01337-7
ER  - 

APA

Johansen, P., Chubb, B., Hunt, B., Malkin, S. J. P., Sandberg, A., & Capehorn, M. (2020). Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK. Advances in Therapy. https://doi.org/10.1007/s12325-020-01337-7

Source records